Anthem Biosciences: Analysis by Nomura

Nomura has started following Anthem Biosciences, giving it a “Buy” rating and predicting the stock will rise to ₹740. This means the stock could increase by 18% from its price on Thursday (₹627.05). They believe Anthem is a good investment because of its strong position in India’s growing field of research, development, and manufacturing services for drugs.

Key Points

• Anthem is in a fast-growing Indian market for drug development services.
• India’s drug development market is expected to grow 13% annually to $15.4 billion by 2029.
• Anthem can create drugs using different methods, including new types of medicines.
• Anthem has strong relationships with many drug companies, both big and small.
• The company runs efficiently with good profits and controls its costs well.
• Nomura forecasts strong growth for Anthem over the next few years, despite some short-term slowdowns.

Anthem Biosciences is helping drug companies create new medicines. The company is particularly good at working with smaller, newer drug companies, which is why Nomura is optimistic. They are focused on helping companies develop drugs quickly and efficiently.

Nomura sees a big opportunity in India’s expanding market for drug development services. This market is growing quickly, and Anthem is well-positioned to take advantage of it. They believe this growth will continue for many years to come.

Anthem operates in a way that allows them to be profitable and control costs. They have built strong relationships with drug companies, which is a key advantage. This combination of factors is why Nomura believes in the company’s future.

Over the next three years, Nomura expects Anthem to grow steadily. However, they anticipate some temporary slowdowns due to the company’s current level of activity. This growth is expected to accelerate in the later years, driven by the launch of new products and expanding production capacity.

Nomura’s target price of ₹740 is based on what the company is expected to earn over the next few years. They believe this price is justified because of Anthem’s strengths and the growing demand for its services.

“Investing in Anthem Biosciences represents a strategic opportunity to capitalize on a dynamic and expanding market with a well-positioned company.”